Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor-associated protein of the synapse (rapsyn) is a cytoplasmic protein encoded by the RAPSN gene and is essential for the normal formation and maintenance of synapses at the neuromuscular junction. Rapsyn anchors and clusters nicotinic acetylcholine receptors (AChRs) at postsynaptic membranes by linking them to the postsynaptic cytoskeleton, likely through direct association with proteins such as actin or spectrin. Loss-of-function mutations in RAPSN disrupt AChR clustering, leading to congenital myasthenic syndrome (CMS), a disorder characterized by muscle weakness and fatigability. Rapsyn is not a receptor, enzyme, or transporter but is critical for receptor localization and synaptic integrity. Disease-causing mutations in RAPSN, most commonly N88K, can reduce the stability of AChR clusters, and patients often respond to acetylcholinesterase inhibitors and other neuromodulatory drugs[1][3][5].
Indirect modulation via enhancement of acetylcholine signaling at the neuromuscular junction (e.g., inhibition of acetylcholinesterase), stabilization of acetylcholine receptor clusters
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Receptor-associated protein of the synapse (rapsyn).